An overview of head and neck tumor reirradiation: what has been achieved so far?

SUMMARY

Received: 1 August 2023 Head and neck cancers (HNCs) are rated 6-7 in global prevalence among malignant tumors, with 700,000 newly registered cases and 470,000 deaths a year. The main risk factors for HNC recurrence are large size of primary tumor and lymph node metastasis; for RT-treated cases, these are complemented by treatment interruptions. The primary RT doses are high: 46-54 Gy for prophylactic lymph node irradiation or ≥66 Gy on tumor bed and affected lymph collectors. High doses of primary RT, along with anatomically intricate locations of tumors (close to critical . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.